Connect with us

Life Sciences

Covenant Physician Partners Now Incorporates Artificial Intelligence System for Enhanced Colonoscopy Screenings in Hawaii

Covenant Physician Partners announces three of their Hawaii locations will offer patients receiving a colonoscopy an enhanced screening with the aid of…

Published

on

This article was originally published by AITHORITY
Covenant Physician Partners Now Incorporates Artificial Intelligence System for Enhanced Colonoscopy Screenings in Hawaii

Covenant Physician Partners announces three of their Hawaii locations will offer patients receiving a colonoscopy an enhanced screening with the aid of GI Genius intelligent endoscopy module. The GI Genius module employs artificial intelligence (AI) to help physicians detect polyps—a powerful new ally in the fight against colorectal cancer.

 Latest Interview Insights : AiThority Interview with Ritu Bhargava, Chief Product Officer at SAP CX

“The GI GeniusTM module is the first and only AI system for detection of colonic polyps in the United States and we are proud to offer it to our patients”

“The AI revolution is already upon us, and poised to dramatically change the face of medicine,” said Yousif A-Rahim, M.D., Ph.D., Chief Medical Officer for Covenant Physician Partners, and author of the book SMARTER MEDICINE. “I am looking forward to GI Genius assisting my colleagues and me increase our already excellent detection rate.”

Covenant Physician Partners’ mission is to promote early detection and treatment of diseases of the colon, stomach, and esophagus. “We rolled out GI Genius first at our Pacific Endoscopy Center in Pearl City and Endoscopy Institute of Hawaii in Honolulu and have plans to introduce GI Genius at The Endoscopy Center in Hilo, next month,” said AnnaLyn Ogata, Covenant’s Regional Vice President for Hawaii.

Read More InterviewAiThority Interview with Anthony Katsur, Chief Executive Officer at IAB Tech Lab

“We’re thrilled with the timing because March is Colorectal Cancer Awareness Month and hopefully this will encourage more people over the age of 45 to get a colonoscopy,” added Dr. A-Rahim. Beyond his role as CMO, Dr. A-Rahim performs procedures at Covenant’s Pacific Endoscopy Center when he’s not lecturing on Medicine at Harvard Medical School.

The GI GeniusTM module uses advanced AI software to highlight suspicious polyps with a visual marker in real time—serving as the gastroenterologist’s ever-vigilant second observer with a sensitivity rate per lesion of 99.7%.1 Studies have shown that AI-assisted colonoscopy can increase polyp detection rates, and every 1% increase in adenoma detection rate reduces the risk of colorectal cancer by 3%.2,3 Colorectal cancer is the third most common form of cancer diagnosed in the U.S., with almost 150,000 new cases every year.4

Covenant Physician Partners in Hawaii is focused on meeting the medical needs of the community by providing its expert staff with the latest technologies and procedures. “The GI GeniusTM module is the first and only AI system for detection of colonic polyps in the United States and we are proud to offer it to our patients,” said Ms. Ogata.

AiThority Interview : AiThority Interview with João Graça, Co-founder and CTO at Unbabel

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Covenant Physician Partners Now Incorporates Artificial Intelligence System for Enhanced Colonoscopy Screenings in Hawaii appeared first on AiThority.



artificial intelligence


medicine

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending